These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15956824)

  • 1. Early recognition and treatment of hypertensive heart disease.
    Mitchell JA; Ventura HO; Mehra MR
    Curr Opin Cardiol; 2005 Jul; 20(4):282-9. PubMed ID: 15956824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and clinical aspects of hypertensive hypertrophy.
    Vogt M; Motz WH; Schwartzkopf B; Strauer BE
    Eur Heart J; 1993 Jul; 14 Suppl D():2-7. PubMed ID: 8103741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aldosterone in left ventricular hypertrophy in hypertension.
    Matsumura K; Fujii K; Oniki H; Oka M; Iida M
    Am J Hypertens; 2006 Jan; 19(1):13-8. PubMed ID: 16461184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular hypertrophy and renin-angiotensin system blockade.
    Cowan BR; Young AA
    Curr Hypertens Rep; 2009 Jun; 11(3):167-72. PubMed ID: 19442324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension and diastolic heart failure.
    Gradman AH; Wilson JT
    Curr Cardiol Rep; 2009 Nov; 11(6):422-9. PubMed ID: 19863866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diastolic dysfunction: a link between hypertension and heart failure.
    Lalande S; Johnson BD
    Drugs Today (Barc); 2008 Jul; 44(7):503-13. PubMed ID: 18806901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD
    Am J Hypertens; 2007 Oct; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
    Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
    Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.
    du Cailar G; Fesler P; Ribstein J; Mimran A
    Hypertension; 2010 Nov; 56(5):865-70. PubMed ID: 20921428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From hypertension to heart failure.
    Papademetriou V
    J Clin Hypertens (Greenwich); 2004 Oct; 6(10 Suppl 2):14-7. PubMed ID: 15470294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.